Douglas Lane & Associates, LLC Biogen Inc. Transaction History

Douglas Lane & Associates, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 21, 2021	SELL	$282.99 - $369.05 $174,321 - $227,334	-616 Closed	0 $0
Q2 2021 Jul 19, 2021	BUY	$259.0 - $414.71 $159,544 - $255,461	616 New	616 $213,000
Q1 2019 Apr 23, 2019	SELL	$216.71 - $338.96 $157,331 - $246,084	-726 Closed	0 $0
Q3 2018 Oct 09, 2018	BUY	$293.51 - $383.83 $213,088 - $278,660	726 New	726 $257,000
Q2 2018 Jul 23, 2018	SELL	$257.52 - $306.91 $212,196 - $252,893	-824 Closed	0 $0
Q1 2018 Apr 23, 2018	SELL	$260.13 - $367.91 $13,006 - $18,395	-50 Reduced 5.72%	824 $226,000
Q4 2017 Jan 24, 2018	BUY	$307.64 - $344.58 $6,152 - $6,891	20 Added 2.34%	874 $278,000
Q3 2017 Oct 19, 2017	BUY	$281.15 - $329.69 $240,102 - $281,555	854	854 $267,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Douglas Lane & Associates, LLC, based on Form 13F filings with the SEC.

Stay updated on Douglas Lane & Associates, LLC with notifications on news.